| Literature DB >> 34087846 |
Naxin Zhao1, Zhili Zeng1, Hongyuan Liang2, Fang Wang2, Di Yang2, Jiang Xiao2, Meiling Chen3, Hongxin Zhao2, Fujie Zhang2, Guiju Gao2.
Abstract
ABSTRACT: Assessing renal function accurately is important for human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) patients. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) recommended three equations to calculate estimated glomerular filtration rate (eGFR). There is evidence that eGFR based on the combination of serum creatinine and cystatin C is the most accurate of the three equations. But there is limited data on the comparison of three CKD-EPI equations in Chinese HIV/AIDS patients. The aim of our study was to compare the three CKD-EPI equations in Chinese HIV/AIDS population and assess renal function.Cross-sectional, single center, prospective study.One hundred seventy two Chinese adult HIV/AIDS patients were enrolled, including 145 (84.3%) males and 27 (15.7%) females. Mean age was 40(±12) years old. Overall mean eGFR based on serum creatinine, cystatin C and the combination of the 2 markers was 112.6(±19.0) mL/min/1.73 m2, 92.0(±24.2)mL/min/1.73 m2, and 101.7(±21.8)mL/min/1.73 m2, respectively (P = .000). The eGFR calculated by serum creatinine alone is higher than eGFR calculated by combination of serum creatinine and cystatin C, and eGFR calculated by cystatin C individual is lower than eGFR calculated by combination of the 2 markers.Of the 3 CKD-EPI equations, the CKD-EPIscr-cys equation may have the most accuracy in evaluating renal function in Chinese HIV/AIDS patients while the CKD-EPIscr equation may overestimate renal function and the CKD-EPIcys equation may underestimate renal function.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34087846 PMCID: PMC8183803 DOI: 10.1097/MD.0000000000026003
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Three CKD-EPI equations for eGFR.
| Subjects | Gender | Scr (mg/dL) | Scys (mg/L) | Equation (mL/min/1.73 m2) |
| eGFRscr | female | ≤0.7 | 141 × (Scr/0.7)−0.329 × 0.993age × 1.018 | |
| >0.7 | 141 × (Scr/0.7)−1.209 × 0.993age × 1.018 | |||
| male | ≤0.9 | 141 × (Scr/0.9)−0.411 × 0.993age | ||
| >0.9 | 141 × (Scr/0.9)−1.209 × 0.993age | |||
| eGFRcys | female | ≤0.8 | 133 × (Scys/0.8)−0.499 × 0.996age × 0.932 | |
| >0.8 | 133 × (Scys/0.8)−1.328 × 0.996age × 0.932 | |||
| male | ≤0.8 | 133 × (Scys/0.8)−0.499 × 0.996age | ||
| >0.8 | 133 × (Scys/0.8)−1.328 × 0.996age | |||
| eGFRscr-cys | female | ≤0.7 | ≤0.8 | 130 × (Scr/0.7)−0.248 × (Scys/0.8)−0.375 × 0.995age |
| >0.8 | 130 × (Scr/0.7)−0.248 × (Scys/0.8)−0.711 × 0.995age | |||
| >0.7 | ≤0.8 | 130 × (Scr/0.7)−0.601 × (Scys/0.8)−0.375 × 0.995age | ||
| >0.8 | 130 × (Scr/0.7)−0.601 × (Scys/0.8)−0.711 × 0.995age | |||
| male | ≤0.9 | ≤0.8 | 135 × (Scr/0.9)−0.207 × (Scys/0.8)−0.375 × 0.995age | |
| >0.8 | 135 × (Scr/0.9)−0.207 × (Scys/0.8)−0.711 × 0.995age | |||
| >0.9 | ≤0.8 | 135 × (Scr/0.9)−0.601 × (Scys/0.8)−0.375 × 0.995age | ||
| >0.8 | 135 × (Scr/0.9)−0.601 × (Scys/0.8)−0.711 × 0.995age |
Main demographic characteristics of 172 HIV/AIDS patients included in the study.
| Variables | Estimates |
| Mean age, yr (±SD) | 40 (±12) |
| Gender, n (%) | |
| Male | 145 (84.3%) |
| Female | 27 (15.7%) |
| Mean body mass index, kg/m2 (±SD) | 22 (±4) |
| Hypertension, n (%) | 17 (9.9%) |
| Diabetes mellitus, n (%) | 13 (7.6%) |
| Dyslipidemia, n (%) | 65 (37.8%) |
| Tumor, n (%) | 14 (8.1%) |
| Hepatitis B coinfection, n (%) | 11 (6.4%) |
| Hepatitis C coinfection, n (%) | 8 (4.7%) |
| Syphilis, n (%) | 43 (25.0%) |
| Median duration of HIV infection, months (IQR) | 12 (0–72) |
| Current ART regimen, n (%) | |
| No treatment | 58 (33.7%) |
| TDF + 3TC + EFV | 66 (38.4%) |
| TDF + 3TC + LPV/r | 18 (10.5%) |
| TDF + 3TC + DTG | 5 (2.9%) |
| EVG/C/TAF/FTC | 5 (2.9%) |
| Others∗ | 20 (11.6%) |
| Current HIV infection status, n (%) | |
| Suppression under treatment (viral load <20 copies/ml) | 69 (40.1%) |
| No suppression (including no treatment) | 103 (59.9%) |
| Median CD4+ T cell count, cells/μL (IQR) | 120 (42–458) |
Differences of mean eGFR calculated by 3 CKD-EPI equations.
| Comparation of variables | Difference of mean (mL/min/1.73 m2) | |
| eGFRscr - eGFRcys | 20.6 | .000 |
| eGFRscr - eGFRscr-cys | 10.9 | .000 |
| eGFRcys- eGFRscr-cys | −9.7 | .000 |
Frequencies and percentages of patients in each eGFR category.
| eGFR category | Number (%) of patients with each eGFR category by 3 equations | ||
| (mL/min/1.73 m2) | CKD-EPIscr | CKD-EPIcys | CKD-EPIscr-cys |
| ≥90 | 154 (89.5%) | 102 (59.3%) | 131 (76.2%) |
| 60–89 | 14 (8.1%) | 53 (30.8%) | 32 (18.6%) |
| 30–59 | 4 (2.3%) | 14 (8.1%) | 8 (4.7%) |
| 15–29 | 0 (0%) | 3 (1.7%) | 1 (0.6%) |
| <15 | 0 (0%) | 0 (0%) | 0 (0%) |
Comparison of eGFR classifications between CKD-EPIscr-cys equation and the other 2 equations.
| eGFRscr-cys (mL/min/1.73 m2) | ||||||
| N | ≥90 | 60–89 | 30–59 | 15–29 | <15 | Total |
| eGFRscr ≥90 | 131 | 22 | 1 | 0 | 0 | 154 |
| 60–89 | 0 | 10 | 4 | 0 | 0 | 14 |
| 30–59 | 0 | 0 | 3 | 1 | 0 | 4 |
| 15–29 | 0 | 0 | 0 | 0 | 0 | 0 |
| <15 | 0 | 0 | 0 | 0 | 0 | 0 |
| eGFRcys ≥90 | 101 | 1 | 0 | 0 | 0 | 102 |
| 60–89 | 30 | 23 | 0 | 0 | 0 | 53 |
| 30–59 | 0 | 8 | 6 | 0 | 0 | 14 |
| 15–29 | 0 | 0 | 2 | 1 | 0 | 3 |
| <15 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 131 | 32 | 8 | 1 | 0 | 172 |